Skip to main content
Premium Trial:

Request an Annual Quote

A Sentence Comes Down

French doctor Yves Benhamou was sentenced yesterday to time served and three years' supervised release after pleading guilty in an insider-trading case, reports Reuters. Benhamou pleaded guilty to securities fraud, making false statements to the US Federal Bureau of Investigation, and conspiracy for passing secrets about Human Genome Sciences' hepatitis C drug trials to Joseph Skowron, a hedge fund manager at FrontPoint Partners, Bloomberg adds. Benhamou was an advisor on the trial. In addition, he was ordered to pay nearly $6 million in restitution, Reuters adds.

"[Skowron] admitted that after Benhamou passed him the non-public information, FrontPoint sold its stock, avoiding $30 million in losses, according to the US," Boomberg says. Skowron was sentenced in November to five years in prison.

The Scan

New Study Highlights Role of Genetics in ADHD

Researchers report in Nature Genetics on differences in genetic architecture between ADHD affecting children versus ADHD that persists into adulthood or is diagnosed in adults.

Study Highlights Pitfall of Large Gene Panels in Clinical Genomic Analysis

An analysis in Genetics in Medicine finds that as gene panels get larger, there is an increased chance of uncovering benign candidate variants.

Single-Cell Atlas of Drosophila Embryogenesis

A new paper in Science presents a single-cell atlas of fruit fly embryonic development over time.

Phage Cocktail Holds Promise for IBD

Researchers uncovered a combination phage therapy that targets Klebsiella pneumonia strains among individuals experiencing inflammatory bowel disease flare ups, as they report in Cell.